Sigma Planning Corp Reduces Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Sigma Planning Corp cut its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 65.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 22,610 shares of the biopharmaceutical company’s stock after selling 43,690 shares during the quarter. Sigma Planning Corp’s holdings in Bristol-Myers Squibb were worth $1,160,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. RFG Advisory LLC increased its holdings in shares of Bristol-Myers Squibb by 13.7% in the 3rd quarter. RFG Advisory LLC now owns 16,952 shares of the biopharmaceutical company’s stock valued at $984,000 after acquiring an additional 2,046 shares during the last quarter. Onyx Bridge Wealth Group LLC boosted its position in Bristol-Myers Squibb by 25.3% during the 3rd quarter. Onyx Bridge Wealth Group LLC now owns 7,226 shares of the biopharmaceutical company’s stock valued at $419,000 after purchasing an additional 1,457 shares during the period. Fifth Third Wealth Advisors LLC boosted its position in Bristol-Myers Squibb by 58.3% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 4,967 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 1,830 shares during the period. BTC Capital Management Inc. boosted its position in Bristol-Myers Squibb by 7.9% during the 3rd quarter. BTC Capital Management Inc. now owns 92,514 shares of the biopharmaceutical company’s stock valued at $5,370,000 after purchasing an additional 6,746 shares during the period. Finally, Advisors Management Group Inc. ADV boosted its position in Bristol-Myers Squibb by 19.9% during the 3rd quarter. Advisors Management Group Inc. ADV now owns 7,717 shares of the biopharmaceutical company’s stock valued at $448,000 after purchasing an additional 1,281 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on BMY. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Wells Fargo & Company boosted their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $68.00 to $60.00 in a research report on Wednesday, January 3rd. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. Finally, StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $61.18.

Bristol-Myers Squibb Stock Up 0.4 %

Shares of Bristol-Myers Squibb stock opened at $49.14 on Tuesday. The stock’s fifty day moving average is $51.22 and its 200-day moving average is $51.38. The firm has a market capitalization of $99.59 billion, a PE ratio of 12.73, a price-to-earnings-growth ratio of 1.48 and a beta of 0.39. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. Bristol-Myers Squibb has a 12-month low of $47.58 and a 12-month high of $70.93.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. The company had revenue of $11.48 billion for the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. Bristol-Myers Squibb’s revenue for the quarter was up .6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.82 earnings per share. Equities analysts anticipate that Bristol-Myers Squibb will post 6.63 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 4.88%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is 62.18%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.